Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
Pasithea Therapeutics will present initial Part A clinical data from its ongoing Phase 1/1b trial of PAS-004 in adults with NF1 at the 2026 European Neurofibromatosis Conference, taking place November 12-14, 2026 in Vienna, Austria. The data will be shown in two formats: an oral presentation on cutaneous neurofibromas by Rebecca Brown, MD of the University of Alabama at Birmingham (Nov 13, 08:00-09:30 CET), and a poster on plexiform neurofibromas presented by CEO Tiago Reis Marques (Nov 12). This will be the company's first public disclosure of clinical data from Part A of the trial, and a follow-up press release with detailed results is planned at the time of presentation.
Key figures
- Drug Name
- PAS-004
- Phase Of Trial
- Phase 1/1b
- Trial Id NF1
- NCT06961565
- Trial Id Cancer
- NCT06299839
- Conference Dates
- November 12-14, 2026
- Conference Location
- Hyatt Regency Vienna, Vienna, Austria
- Presentation Formats
- ["oral presentation on cutaneous neurofibromas (CN)","poster presentation on plexiform neurofibromas (PN)"]
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.